Cite
Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections.
MLA
Lim, Wey Wen, et al. “Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections.” The Journal of Infectious Diseases, vol. 230, no. 1, July 2024, pp. 152–60. EBSCOhost, https://doi.org/10.1093/infdis/jiae122.
APA
Lim, W. W., Feng, S., Wong, S.-S., Sullivan, S. G., & Cowling, B. J. (2024). Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections. The Journal of Infectious Diseases, 230(1), 152–160. https://doi.org/10.1093/infdis/jiae122
Chicago
Lim, Wey Wen, Shuo Feng, Sook-San Wong, Sheena G Sullivan, and Benjamin J Cowling. 2024. “Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections.” The Journal of Infectious Diseases 230 (1): 152–60. doi:10.1093/infdis/jiae122.